The Federal Trade Commission and the pharmacy benefit managers it’s accusing of artificially inflating insulin prices are hitting a host of prominent companies, from McDonald’s to the HR consultancy Mercer, with massive document requests in search of information to buttress their positions.
Since the FTC brought its case in September, at least 10 nonparty companies—from insulin makers to past and current clients of the PBMs—have received subpoenas. McDonald’s said in a Jan. 31 filing that it had fully complied with the FTC’s subpoena after reviewing thousands of documents and submitting more than 1,300 but was still working on producing documents for PBMs.
